company background image
MGNX

MacroGenics NasdaqGS:MGNX Stock Report

Last Price

US$3.98

Market Cap

US$244.1m

7D

-4.3%

1Y

-86.7%

Updated

21 May, 2022

Data

Company Financials +
MGNX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MGNX Stock Overview

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.

MacroGenics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MacroGenics
Historical stock prices
Current Share PriceUS$3.98
52 Week HighUS$32.81
52 Week LowUS$3.76
Beta2.11
1 Month Change-51.46%
3 Month Change-60.75%
1 Year Change-86.70%
3 Year Change-78.89%
5 Year Change-78.19%
Change since IPO-84.07%

Recent News & Updates

May 09
The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

The analysts covering MacroGenics, Inc. ( NASDAQ:MGNX ) delivered a dose of negativity to shareholders today, by making...

Shareholder Returns

MGNXUS BiotechsUS Market
7D-4.3%1.4%-2.7%
1Y-86.7%-21.7%-12.9%

Return vs Industry: MGNX underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: MGNX underperformed the US Market which returned -12.7% over the past year.

Price Volatility

Is MGNX's price volatile compared to industry and market?
MGNX volatility
MGNX Average Weekly Movement12.9%
Biotechs Industry Average Movement12.4%
Market Average Movement7.9%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: MGNX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: MGNX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2000427Scott Koenighttps://www.macrogenics.com

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.

MacroGenics Fundamentals Summary

How do MacroGenics's earnings and revenue compare to its market cap?
MGNX fundamental statistics
Market CapUS$244.11m
Earnings (TTM)-US$217.29m
Revenue (TTM)US$71.67m

3.4x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MGNX income statement (TTM)
RevenueUS$71.67m
Cost of RevenueUS$225.58m
Gross Profit-US$153.91m
Other ExpensesUS$63.38m
Earnings-US$217.29m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.54
Gross Margin-214.76%
Net Profit Margin-303.19%
Debt/Equity Ratio0%

How did MGNX perform over the long term?

See historical performance and comparison

Valuation

Is MacroGenics undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.37x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MGNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MGNX's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: MGNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MGNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MGNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MGNX's PB Ratio (1.4x) is in line with the US Biotechs industry average.


Future Growth

How is MacroGenics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MGNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MGNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MGNX's revenue (15.1% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: MGNX's revenue (15.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MGNX is forecast to be unprofitable in 3 years.


Past Performance

How has MacroGenics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-17.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MGNX is currently unprofitable.

Growing Profit Margin: MGNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MGNX is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.

Accelerating Growth: Unable to compare MGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: MGNX has a negative Return on Equity (-121.92%), as it is currently unprofitable.


Financial Health

How is MacroGenics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MGNX's short term assets ($218.2M) exceed its short term liabilities ($67.1M).

Long Term Liabilities: MGNX's short term assets ($218.2M) exceed its long term liabilities ($26.1M).


Debt to Equity History and Analysis

Debt Level: MGNX is debt free.

Reducing Debt: MGNX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MGNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.6% each year


Dividend

What is MacroGenics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGNX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MGNX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Scott Koenig (69 yo)

20.67yrs

Tenure

US$4,868,514

Compensation

Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD4.87M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MGNX's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: MGNX's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

MacroGenics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: MacroGenics, Inc.
  • Ticker: MGNX
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$244.107m
  • Shares outstanding: 61.33m
  • Website: https://www.macrogenics.com

Number of Employees


Location

  • MacroGenics, Inc.
  • 9704 Medical Center Drive
  • Rockville
  • Maryland
  • 20850
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.